Rituximab intrathecal injection combined with intravenous chemotherapy in the successful treatment of splenic marginal zone lymphoma with the central nervous system relapse: a case report and literatures review
10.3760/cma.j.issn.1009-9921.2013.07.011
- VernacularTitle:利妥昔单抗鞘注联合静脉化疗治疗脾边缘区淋巴瘤中枢神经系统复发一例并文献复习
- Author:
Xiaochen CHEN
;
Zhengming JIN
;
Yue HAN
;
Lingchuan GUO
;
Depei WU
- Publication Type:Journal Article
- Keywords:
Rituximab;
Injections,spinal;
Splenic marginal zone lymphoma;
Central nervous system;
Recurrence
- From:
Journal of Leukemia & Lymphoma
2013;22(7):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical characteristics,pathological features,therapy and prognosis of a case of splenic marginal zone lymphoma (SMZL) with central recurrence,evaluation the safety and efficacy of rituximab intrathecal injection combined with intravenous chemotherapy.Methods Retrospectively analyze the case of SMZL with the central recurrence,and review the relevant literatures.Results According to the tests of MICM of bone marrow,spleen pathology,PET-CT and laboratory examination (LDH),patient was diagnosed as SMZL,IV group B,IPI and aaIPI was high risk group.After first-line therapy,the patient achieved complete remission.But then the central nervous system relapsed.The patients was treated with rituximab intrathecal injection combined with intravenous chemotherapy,the central focus disappeared.Conclusion SMZL belongs to low-grade lymphoma,which combined with central nervous system relapse is very rare.Rituximab intrathecal injection combined with intravenous chemotherapy in the treatment of the patients is safe to use,and have good clinical efficacy.
